SE9301581D0 - Protein formulation - Google Patents
Protein formulationInfo
- Publication number
- SE9301581D0 SE9301581D0 SE19939301581A SE9301581A SE9301581D0 SE 9301581 D0 SE9301581 D0 SE 9301581D0 SE 19939301581 A SE19939301581 A SE 19939301581A SE 9301581 A SE9301581 A SE 9301581A SE 9301581 D0 SE9301581 D0 SE 9301581D0
- Authority
- SE
- Sweden
- Prior art keywords
- factor viii
- pct
- aqueous solution
- present
- activity
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000001690 Factor VIII Human genes 0.000 abstract 5
- 108010054218 Factor VIII Proteins 0.000 abstract 5
- 229960000301 factor viii Drugs 0.000 abstract 4
- 239000007864 aqueous solution Substances 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229940126534 drug product Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000011261 inert gas Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 230000000717 retained effect Effects 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229940105778 coagulation factor viii Drugs 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939301581A SE9301581D0 (sv) | 1993-05-07 | 1993-05-07 | Protein formulation |
PL94311567A PL174866B1 (pl) | 1993-05-07 | 1994-03-24 | Sposób wytwarzania leku zawierającego czynnik krzepnięcia VIII |
JP52470394A JP3751633B2 (ja) | 1993-05-07 | 1994-03-24 | 因子viiiの酸素低減水溶液 |
PCT/SE1994/000265 WO1994026286A1 (en) | 1993-05-07 | 1994-03-24 | Oxygen-reduced aqueous solution of factor viii |
SK1383-95A SK283002B6 (sk) | 1993-05-07 | 1994-03-24 | Prípravok s obsahom koagulačného faktora VIII |
PT94915307T PT700299E (pt) | 1993-05-07 | 1994-03-24 | Solucao aquosa de factor viii com teor de oxigenio reduzido |
ES94915307T ES2177579T3 (es) | 1993-05-07 | 1994-03-24 | Solucion acuosa de factor viii de bajo contenido en oxigeno. |
AU66597/94A AU681883B2 (en) | 1993-05-07 | 1994-03-24 | Oxygen-reduced aqueous solution of factor VIII |
CZ19952869A CZ293527B6 (cs) | 1993-05-07 | 1994-03-24 | Formulace s obsahem koagulačního faktoru VIII a způsob její přípravy |
CA002161350A CA2161350C (en) | 1993-05-07 | 1994-03-24 | Oxygen-reduced aqueous solution of factor viii |
EP94915307A EP0700299B1 (en) | 1993-05-07 | 1994-03-24 | Oxygen-reduced aqueous solution of factor viii |
NZ266031A NZ266031A (en) | 1993-05-07 | 1994-03-24 | Factor viii composition with reduced dissolved oxygen |
HU9503171A HU215263B (hu) | 1993-05-07 | 1994-03-24 | VIII faktor csökkentett oxigéntartalmú vizes oldata |
CN94192021A CN1113655C (zh) | 1993-05-07 | 1994-03-24 | 氧降低的凝固因子vⅲ水溶液 |
DE69430745T DE69430745T2 (de) | 1993-05-07 | 1994-03-24 | Sauerstoff reduzierte wässerige faktor viii-enthaltene lösung |
RU95121755A RU2142290C1 (ru) | 1993-05-07 | 1994-03-24 | Водный раствор фактора viii со сниженной концентрацией кислорода |
AT94915307T ATE218354T1 (de) | 1993-05-07 | 1994-03-24 | Sauerstoff reduzierte wässerige faktor viii- enthaltene lösung |
US08/535,251 US5962650A (en) | 1993-05-07 | 1994-03-24 | Oxygen-reduced aqueous solution of factor VIII |
DK94915307T DK0700299T3 (da) | 1993-05-07 | 1994-03-24 | Oxygen-reduceret, vandig faktor VIII-opløsning |
KR1019950704933A KR100304143B1 (ko) | 1993-05-07 | 1994-03-24 | 산소가감소된인자viii의수용액 |
ZA942251A ZA942251B (en) | 1993-05-07 | 1994-04-02 | Protein formulation. |
EE9400380A EE03118B1 (et) | 1993-05-07 | 1994-11-17 | Proteiinravim ja selle valmistamismeetod |
FI955305A FI111910B (fi) | 1993-05-07 | 1995-11-06 | Menetelmä hyytymistekijää VIII sisältävän lääkeainevalmisteen valmistamiseksi |
NO19954457A NO321769B1 (no) | 1993-05-07 | 1995-11-07 | Oksygenredusert vandig opplosning av faktor VIII og fremgangsmate for fremstilling av denne. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939301581A SE9301581D0 (sv) | 1993-05-07 | 1993-05-07 | Protein formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9301581D0 true SE9301581D0 (sv) | 1993-05-07 |
Family
ID=20389868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE19939301581A SE9301581D0 (sv) | 1993-05-07 | 1993-05-07 | Protein formulation |
Country Status (24)
Country | Link |
---|---|
US (1) | US5962650A (et) |
EP (1) | EP0700299B1 (et) |
JP (1) | JP3751633B2 (et) |
KR (1) | KR100304143B1 (et) |
CN (1) | CN1113655C (et) |
AT (1) | ATE218354T1 (et) |
AU (1) | AU681883B2 (et) |
CA (1) | CA2161350C (et) |
CZ (1) | CZ293527B6 (et) |
DE (1) | DE69430745T2 (et) |
DK (1) | DK0700299T3 (et) |
EE (1) | EE03118B1 (et) |
ES (1) | ES2177579T3 (et) |
FI (1) | FI111910B (et) |
HU (1) | HU215263B (et) |
NO (1) | NO321769B1 (et) |
NZ (1) | NZ266031A (et) |
PL (1) | PL174866B1 (et) |
PT (1) | PT700299E (et) |
RU (1) | RU2142290C1 (et) |
SE (1) | SE9301581D0 (et) |
SK (1) | SK283002B6 (et) |
WO (1) | WO1994026286A1 (et) |
ZA (1) | ZA942251B (et) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
US5929031A (en) * | 1995-05-02 | 1999-07-27 | Baxter Biotech Technology Sarl | Storage stable hemoglobin solutions |
US5925738A (en) * | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
DE60035260T2 (de) * | 1999-02-22 | 2007-10-18 | The University Of Connecticut, Farmington | Neue albuminfreie faktor viii formulierungen |
NZ516400A (en) * | 1999-07-13 | 2004-02-27 | Biovitrum Ab | Stable factor VIII compositions |
JP3466516B2 (ja) | 1999-09-07 | 2003-11-10 | 科学技術振興事業団 | 安定保存可能な酸素輸液剤 |
AU2002351755A1 (en) * | 2001-12-21 | 2003-07-15 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
EP1458408B1 (en) | 2001-12-21 | 2009-04-15 | Novo Nordisk Health Care AG | Liquid composition of factor vii polypeptides |
GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
EP1517698B2 (en) * | 2002-06-21 | 2017-12-06 | Novo Nordisk Health Care AG | STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
WO2004103398A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
JP4658041B2 (ja) * | 2003-06-25 | 2011-03-23 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドの液体組成物 |
ATE446768T1 (de) * | 2003-07-01 | 2009-11-15 | Novo Nordisk Healthcare Ag | Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden |
EP1656158B1 (en) | 2003-08-14 | 2016-03-09 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
EP2298287B1 (en) | 2003-12-19 | 2018-04-11 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
SI1750733T1 (sl) | 2004-05-03 | 2014-03-31 | Emory University | POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B |
US7504377B2 (en) | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
US7494974B2 (en) | 2006-10-24 | 2009-02-24 | Ikor, Inc. | Carboxymethylated cross-linked tetrameric hemoglobin |
ATE471158T1 (de) * | 2007-04-17 | 2010-07-15 | Schwabe Willmar Gmbh & Co | Verfahren zur herstellung von lagerstabilen lösungen aus pelargonium-extrakten |
JP5323072B2 (ja) * | 2007-07-11 | 2013-10-23 | ノボ・ノルデイスク・エー/エス | 混合方式又は多様式樹脂を使用する第viii因子の精製 |
EP2113564A1 (en) | 2008-05-01 | 2009-11-04 | Arecor Limited | Protein formulation |
JP2012500250A (ja) | 2008-08-21 | 2012-01-05 | オクタファルマ アクチェン ゲゼルシャフト | 組換えにより産生したヒト第viii及び第ix因子 |
CA2735376C (en) * | 2008-09-03 | 2016-11-29 | Octapharma Ag | New protecting compositions for recombinantly produced factor viii |
NZ593190A (en) | 2008-11-07 | 2013-01-25 | Baxter Int | Factor viii formulations |
US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
NO2440239T3 (et) | 2009-06-09 | 2018-02-10 | ||
US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
GB0915480D0 (en) * | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
EP4091645A1 (en) | 2010-08-25 | 2022-11-23 | Hemanext Inc. | Method for enhancing red blood cell quality and survival during storage |
KR101948337B1 (ko) | 2010-11-05 | 2019-02-14 | 박스알타 인코퍼레이티드 | 증가된 특이 활성도를 갖는 항혈우병 인자 viii의 신규 변이체 |
ES2957338T3 (es) | 2010-11-05 | 2024-01-17 | Hemanext Inc | Irradiación de glóbulos rojos y almacenamiento anaeróbico |
US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
ES2923571T3 (es) | 2011-08-10 | 2022-09-28 | Hemanext Inc | Dispositivo integrado de filtrado de leucocitos, oxígeno y/o CO2 y separación de plasma |
EP3967143A1 (en) | 2013-02-28 | 2022-03-16 | Hemanext Inc. | Gas addition device for blood treatment and corresponding method |
ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
IL299978B1 (en) | 2015-03-10 | 2024-04-01 | Hemanext Inc | Single-use oxygen reduction kits, devices and methods for their use |
KR20240067253A (ko) | 2015-04-23 | 2024-05-16 | 헤마넥스트 인코포레이티드 | 혐기성 혈액 저장 용기 |
MX2017014812A (es) | 2015-05-18 | 2018-05-11 | New Health Sciences Inc | Metodos para el almacenamiento de sangre completa y composiciones de esta. |
CN109195632A (zh) | 2016-05-27 | 2019-01-11 | 新健康科学股份有限公司 | 厌氧血液储存和病原体失活方法 |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2896381A (en) * | 1954-05-27 | 1959-07-28 | Hodes Lange Corp | Method and apparatus for treating and filling ampoules |
US3143471A (en) * | 1962-01-18 | 1964-08-04 | Merck & Co Inc | Argon method of drying and preserving lyophilized therapeutic products |
US4165370A (en) * | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
DE3144705C2 (de) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
US4481189A (en) * | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
US4727027A (en) * | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
ATE52922T1 (de) * | 1985-08-05 | 1990-06-15 | Immuno Ag | Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren. |
US4709819A (en) * | 1986-07-23 | 1987-12-01 | Environmental Diagnostics, Inc. | Method for preserving plated media and product |
CA1292686C (en) * | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
CA1329760C (en) * | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
FR2630115B1 (fr) * | 1988-04-14 | 1994-10-28 | Merieux Inst | Procede de stabilisation des solutions d'albumine humaine et solution obtenue |
GB8808810D0 (en) * | 1988-04-14 | 1988-05-18 | Biopharm Clinical Research Ltd | Heparin-containing formulations |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
AU697204B2 (en) * | 1994-10-31 | 1998-10-01 | Kimberly-Clark Worldwide, Inc. | High density nonwoven filter media |
-
1993
- 1993-05-07 SE SE19939301581A patent/SE9301581D0/xx unknown
-
1994
- 1994-03-24 CZ CZ19952869A patent/CZ293527B6/cs not_active IP Right Cessation
- 1994-03-24 PL PL94311567A patent/PL174866B1/pl not_active IP Right Cessation
- 1994-03-24 WO PCT/SE1994/000265 patent/WO1994026286A1/en active IP Right Grant
- 1994-03-24 CN CN94192021A patent/CN1113655C/zh not_active Expired - Fee Related
- 1994-03-24 ES ES94915307T patent/ES2177579T3/es not_active Expired - Lifetime
- 1994-03-24 DK DK94915307T patent/DK0700299T3/da active
- 1994-03-24 AU AU66597/94A patent/AU681883B2/en not_active Ceased
- 1994-03-24 HU HU9503171A patent/HU215263B/hu not_active IP Right Cessation
- 1994-03-24 DE DE69430745T patent/DE69430745T2/de not_active Expired - Lifetime
- 1994-03-24 PT PT94915307T patent/PT700299E/pt unknown
- 1994-03-24 KR KR1019950704933A patent/KR100304143B1/ko not_active IP Right Cessation
- 1994-03-24 JP JP52470394A patent/JP3751633B2/ja not_active Expired - Fee Related
- 1994-03-24 SK SK1383-95A patent/SK283002B6/sk not_active IP Right Cessation
- 1994-03-24 RU RU95121755A patent/RU2142290C1/ru not_active IP Right Cessation
- 1994-03-24 NZ NZ266031A patent/NZ266031A/en not_active IP Right Cessation
- 1994-03-24 US US08/535,251 patent/US5962650A/en not_active Expired - Lifetime
- 1994-03-24 AT AT94915307T patent/ATE218354T1/de active
- 1994-03-24 EP EP94915307A patent/EP0700299B1/en not_active Expired - Lifetime
- 1994-03-24 CA CA002161350A patent/CA2161350C/en not_active Expired - Fee Related
- 1994-04-02 ZA ZA942251A patent/ZA942251B/xx unknown
- 1994-11-17 EE EE9400380A patent/EE03118B1/et not_active IP Right Cessation
-
1995
- 1995-11-06 FI FI955305A patent/FI111910B/fi not_active IP Right Cessation
- 1995-11-07 NO NO19954457A patent/NO321769B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9301581D0 (sv) | Protein formulation | |
BR9607922A (pt) | Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final | |
CA1158551A (en) | Plasminogen preparations | |
ATE73671T1 (de) | Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin. | |
EE9700218A (et) | Trombiini inhibiitorit sisaldav säilituskindel vesilahus süstimiseks | |
SE9402119D0 (sv) | Solution | |
HU9500021D0 (en) | Methods for preventing degradation of protein c | |
TH19245A (th) | วิธีป้องกันการสลายของโปรตีนซี |